4D Molecular Therapeutics (FDMT) AI Stock Analysis

• Market Cap: $399.31M
• Dividend Yield: N/A
• Average Volume (3M): 629.71K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 227
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 46,702,470
• 10 Day Avg. Volume: 737,993
• 30 Day Avg. Volume: 629,710
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.16
• Enterprise Value/Revenue: -1.90K
• Enterprise Value/Gross Profit: 17.22
• Enterprise Value/Ebitda: 0.28
• 1Y Price Target: $31.80
• Price Target Upside: 271.93% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 52 Neutral
• Price Target: $5.50 ▼(-35.67% Downside)

The company's stock score is primarily impacted by its financial challenges, with persistent negative income and cash flow issues despite a strong cash position on the balance sheet. Positive technical indicators provide some optimism, but the lack of profitability and a negative P/E ratio weigh heavily on the valuation.

Positive Factors

Strong Cash Position

A strong cash position provides financial flexibility, allowing the company to invest in R&D and weather operational challenges without immediate liquidity concerns.

Phase 3 Program Progress

The accelerated timeline for Phase 3 trials indicates strong progress in drug development, potentially leading to earlier commercialization and revenue generation.

Cost Reduction Measures

Significant cost savings from workforce reduction can extend the cash runway, allowing the company to focus resources on critical R&D activities and improve long-term financial health.

Negative Factors

Negative Cash Flow

Persistent negative cash flow indicates ongoing cash burn, which can strain resources and necessitate additional financing, impacting long-term sustainability.

Leadership Change

Leadership changes can disrupt strategic continuity and may affect investor confidence, potentially impacting the company's ability to execute its long-term plans effectively.

Negative Income Trends

Ongoing negative income trends highlight challenges in reaching profitability, which can limit reinvestment capabilities and affect long-term growth prospects.

4D Molecular Therapeutics Business Overview & Revenue Model

Company Description

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

How the Company Makes Money

4D Molecular Therapeutics generates revenue through a combination of partnerships, collaborations, and licensing agreements with pharmaceutical and biotechnology companies. The company may receive upfront payments, research funding, and milestone payments as it advances its therapeutic candidates through clinical trials. Additionally, FDMT could earn royalties on future sales of products developed through these collaborations. Significant partnerships with larger pharmaceutical firms enhance its financial stability and provide access to broader resources for development and commercialization efforts.

4D Molecular Therapeutics Financial Statement Overview

Summary

4D Molecular Therapeutics faces significant financial challenges typical of the biotechnology sector, particularly in early-stage development without consistent revenue streams. The balance sheet shows improvement with a strong cash position, but negative income and cash flow trends highlight ongoing operational hurdles.

Income Statement

The company has experienced erratic revenue trends with significant fluctuations over the years. The lack of revenue in 2024 compared to the previous year denotes a challenging operational environment. Negative net income has been persistent, showcasing difficulties in achieving profitability. Margins are negative, and although the company had some revenue growth in prior years, sustainability remains questionable.

Balance Sheet

The company's balance sheet shows a strong equity base due to significant cash holdings, which is a positive aspect. However, the company's financial stability is undermined by negative equity in previous years. Recent improvements in stockholders' equity and low debt levels indicate improving financial health, but past fluctuations present a risk.

Cash Flow

Cash flow from operations is consistently negative, reflecting ongoing cash burn typical of early-stage biotech companies. While free cash flow remains negative, the increase in financing activities suggests reliance on external funding to sustain operations. Positive trends in financing cash flow are countered by high levels of capital expenditure.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.00K	37.00K	20.72M	3.13M	18.04M	13.61M
Gross Profit	-3.64M	37.00K	-76.37M	-751.00K	15.02M	-39.43M
EBITDA	-221.79M	-187.84M	-107.12M	-106.15M	-68.31M	-55.22M
Net Income	-196.14M	-160.87M	-100.84M	-101.08M	-68.30M	-56.54M
Balance Sheet
Total Assets	473.64M	560.38M	339.89M	261.85M	353.49M	288.33M
Cash, Cash Equivalents and Short-Term Investments	293.23M	424.88M	288.23M	218.64M	315.43M	276.73M
Total Debt	23.08M	24.61M	14.67M	16.12M	16.45M	0.00
Total Liabilities	52.75M	49.78M	32.06M	30.51M	560.48M	31.94M
Stockholders Equity	420.89M	510.61M	307.83M	-314.49M	-207.00M	256.39M
Cash Flow
Free Cash Flow	-166.28M	-138.37M	-78.56M	-98.22M	-78.24M	-51.91M
Operating Cash Flow	-166.39M	-134.59M	-75.79M	-86.69M	-69.13M	-50.91M
Investing Cash Flow	52.46M	-302.44M	115.72M	-17.05M	-172.68M	-1.00M
Financing Cash Flow	2.03M	337.25M	156.83M	3.08M	118.09M	278.98M

4D Molecular Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.55
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 8.55 is above the 20-day moving average (MA) of 7.59, above the 50-day MA of 6.70, and above the 200-day MA of 4.87, indicating a bullish trend. The MACD of 0.61 indicates Negative momentum. The RSI at 67.86 is Neutral, neither overbought nor oversold. The STOCH value of 81.67 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.

4D Molecular Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	52 Neutral	$399.31M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ASMB	49 Neutral	$368.77M	―	-147.64%	―	54.77%	37.35%
DSGN	47 Neutral	$342.54M	―	-26.77%	―	―	-24.60%
KRRO	45 Neutral	$429.35M	―	-58.34%	―	―	61.73%
AURA	43 Neutral	$373.96M	―	-55.39%	―	―	-9.14%
IMRX	27 Underperform	$395.26M	―	-130.47%	―	―	0.66%

4D Molecular Therapeutics Corporate Events

4D Molecular Therapeutics Updates Phase 3 Program for Wet AMD

On June 27, 2025, Uneek Mehra announced his resignation as Chief Financial and Business Officer of 4D Molecular Therapeutics, effective July 15, 2025, to pursue other opportunities. He will continue to provide advisory services until September 2025, ensuring a smooth transition. The company has started searching for a successor. On July 2, 2025, the company provided updates on its Phase 3 program for wet AMD, noting that enrollment for the 4FRONT-1 trial exceeded expectations, leading to an accelerated timeline for topline data in early 2027. Additionally, the 4FRONT-2 trial began ahead of schedule. The company also announced a 25% workforce reduction in July 2025 to streamline operations, resulting in significant cost savings and extending its cash runway into 2028.

4D Molecular Therapeutics Holds Annual Stockholders Meeting

On June 17, 2025, 4D Molecular Therapeutics held its Annual Meeting of Stockholders virtually, where 38,470,536 shares were voted on four proposals. The stockholders elected Class II directors, ratified the selection of PricewaterhouseCoopers LLP as the independent auditor, approved executive compensation, and decided to hold annual advisory votes on executive compensation.